Shares Of Alnylam Pharmaceuticals Dip Lower After Company Announces Its 2016 Pipeline Goals Towards 'Alnylam 2020'

Shares of

were trading lower by nearly 7 percent at $78.74 mid-Monday afternoon after the company

its pipeline goals for 2016 across its various segments. Alnylam Pharmaceuticals noted that by the end of 2020 it expects to achieve a profile with 3 marketed products, 10 RNAi therapeutic clinical programs, including 4 in late stages of developments - across its 3 STArs. As part of Alnylam Pharmaceuticals' 2016 guidance, the company "plans to advance multiple Phase 3 programs, including the start of two fitusiran Phase 3 trials in hemophilia, and expects to have at least ten major clinical data readouts and to file three new IND applications." "We believe the pipeline goals we are announcing today bring us closer to achieving our ‘Alnylam 2020' profile and becoming a fully integrated commercial-stage biopharmaceutical company," said John Maraganore, Ph.D., Chief Executive Officer of Alnylam.